Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00474
|
|||||
| Drug Name |
Clozapine
|
|||||
| Synonyms |
3-chloro-6-(4-methylpiperazin-1-yl)-5H-benzo[b][1,4]benzodiazepine; 8-Chloro-11-(4-methyl)-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo (b,e)(1,4)diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine; 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]-diazepine; 8-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; 8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; Asaleptin; C 6305; CLOZARIL; Clopine (TN); Clorazil; Clozapin; Clozapina; Clozapina [INN-Spanish]; Clozapine (JAN/USP/INN); Clozapine [USAN:INN:BAN]; Clozapine(tautomer); Clozapinum; Clozapinum [INN-Latin]; Clozaril (TN); Denzapine (TN); Fazaclo; Fazaclo (TN); Fazaclo ODT; Froidir (TN); HF-1854; HF1854; Iprox; KS-1166; Klozapol (TN); LEX-123; LX 100-129; Leponex; Leponex (TN); Lepotex; W-801; Zaponex (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Schizophrenia [ICD11: 6A20] | Approved | [1] | |||
| Therapeutic Class |
Antipsychotic Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C18H19ClN4
|
|||||
| Canonical SMILES |
CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
|
|||||
| InChI |
InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3
|
|||||
| InChIKey |
QZUDBNBUXVUHMW-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 5786-21-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 326.8 | Topological Polar Surface Area | 30.9 | ||
| Heavy Atom Count | 23 | Rotatable Bond Count | 1 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 3 | |||
| XLogP |
3.1
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10321650
, 10528074
, 11110967
, 11110968
, 11113341
, 11120316
, 11120804
, 11121292
, 11121655
, 11122135
, 11335518
, 11360757
, 11362724
, 11363013
, 11365286
, 11365575
, 11367848
, 11368137
, 11370719
, 11370720
, 11373074
, 11373449
, 11374475
, 11376010
, 11376299
, 11461729
, 11466378
, 11467498
, 11484534
, 11486076
, 11488735
, 11491643
, 11492713
, 11493953
, 12013419
, 14826474
, 17404839
, 24277892
, 26612026
, 26680236
, 26747001
, 26747002
, 4821023
, 631806
, 7847349
, 7978980
, 8004367
, 8149634
, 855811
, 9141
|
|||||
| ChEBI ID |
ChEBI:3766
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | P-GP | Transporter Info | Km = 58 microM | Baculovirus-infected insect cells-MDR1 | [3] | |
| References | ||||||
| 1 | Clozapine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75. | |||||
| 3 | In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.